Evaluation of anti-tumor efficacy of injectable Centchroman in mice bearing Ehrlich ascites carcinoma.

Abstract

Anti-tumor efficacy of Centchroman formulated as niosomes and gel implant was evaluated in Swiss albino mice bearing Ehrlich ascites carcinoma at 10 mg/kg body weight dose given subcutaneously. Median day of death, percentage increase in host life span and changes in body weight were studied. Centchroman significantly (P < 0.05) increased the median day of death both in free and formulated systems. Also, injectable formulations exhibited a significant (P < 0.05) increase in host life span compared to free drug, hence, enhanced anti-tumor efficacy against Ehrlich ascites carcinoma.

• Authors: B D Shenoy, N Udupa, R Kamath, P U Devi
• Journal: Indian journal of physiology and pharmacology (Indian J Physiol Pharmacol) Vol. 43 Issue 2 Pg. 259-62 (Apr 1999) ISSN: 0019-5499 [Print] India
• PMID: 10365323 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Centchroman

Topics

• Animals
• Antineoplastic Agents (therapeutic use, toxicity)
• Body Weight (drug effects)
• Carcinoma, Ehrlich Tumor (drug therapy)
• Centchroman (therapeutic use, toxicity)
• Chemistry, Pharmaceutical
• Drug Screening Assays, Antitumor
• Mice